StreetInsider.com News Articles

Goldman Sachs Assumes Krystal Biotech (KRYS) at Buy

Thu, 24 Sep 2026 05:36:06 -0400

(Updated - September 24, 2026 5:36 AM EDT)

Goldman Sachs analyst Andrea Newkirk assumes coverage on Krystal Biotech (NASDAQ: KRYS) with a Buy rating and a price target of $441.00.

The analyst comments "KRYS is a profitable, commercial-stage, global biotechnology company leveraging its redosable HSV-1-based gene therapy platform for the treatment of rare diseases. Its lead commercial drug Vyjuvek (topical gel) is the first approved treatment for dystrophic epidermolysis bullosa (DEB; genetic skin condition characterized by blisters, wounds, and scars), where it has achieved 60%+ penetration in US markets and is actively scaling an exUS rollout. KRYS also boasts an extensive clinical

Goldman Sachs Assumes Krystal Biotech (KRYS) at Buy

Thu, 24 Sep 2026 05:36:06 -0400

(Updated - September 24, 2026 5:36 AM EDT)

Goldman Sachs analyst Andrea Newkirk assumes coverage on Krystal Biotech (NASDAQ: KRYS) with a Buy rating and a price target of $441.00.

Form 4 Krystal Biotech, Inc. For: Sep 14 Filed by: ROSSI DINO A

Wed, 16 Sep 2026 20:05:00 -0400

si-local-file:///var/storage/secattach/20260916/27071539.html

Form 4 Krystal Biotech, Inc. For: Sep 14 Filed by: Sutherland Everett Rand

Wed, 16 Sep 2026 20:03:00 -0400

si-local-file:///var/storage/secattach/20260916/27071536.html

Form 4 Krystal Biotech, Inc. For: Sep 14 Filed by: Mason Christopher

Wed, 16 Sep 2026 20:02:00 -0400

si-local-file:///var/storage/secattach/20260916/27071532.html

Form 4 Krystal Biotech, Inc. For: Sep 14 Filed by: Mazzacco Catherine

Wed, 16 Sep 2026 20:02:00 -0400

si-local-file:///var/storage/secattach/20260916/27071535.html

Form 4 Krystal Biotech, Inc. For: Sep 14 Filed by: Gangolli Julian S

Wed, 16 Sep 2026 20:01:00 -0400

si-local-file:///var/storage/secattach/20260916/27071528.html

Form 4 Krystal Biotech, Inc. For: Sep 14 Filed by: JANNEY DANIEL

Wed, 16 Sep 2026 20:01:00 -0400

si-local-file:///var/storage/secattach/20260916/27071531.html

Form 4 Krystal Biotech, Inc. For: Aug 14 Filed by: ROSSI DINO A

Fri, 14 Aug 2026 18:23:00 -0400

si-local-file:///var/storage/secattach/20260814/26933125.html

Form 4 Krystal Biotech, Inc. For: Aug 14 Filed by: ROSSI DINO A

Fri, 14 Aug 2026 18:23:00 -0400

si-local-file:///var/storage/secattach/20260814/26933125.html

Form 144 Krystal Biotech, Inc. Filed by: ROSSI DINO A

Fri, 14 Aug 2026 17:22:00 -0400

si-local-file:///var/storage/secattach/20260814/26932828.html

Form 144 Krystal Biotech, Inc. Filed by: ROSSI DINO A

Fri, 14 Aug 2026 17:22:00 -0400

si-local-file:///var/storage/secattach/20260814/26932828.html

RBC Capital Starts Krystal Biotech (KRYS) at Outperform

Fri, 14 Aug 2026 05:28:07 -0400

RBC Capital initiates coverage on Krystal Biotech (NASDAQ: KRYS) with a Outperform rating and a price target of $400.00.

For an analyst ratings summary and ratings history on Krystal Biotech click here. For more ratings news on Krystal Biotech click here.

Shares of Krystal Biotech closed at $328.34 yesterday.

Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill It